首页 | 本学科首页   官方微博 | 高级检索  
     

肾移植2,3,5年患者的免疫抑制用药分析
引用本文:齐隽 闵志廉. 肾移植2,3,5年患者的免疫抑制用药分析[J]. 肾脏病与透析肾移植杂志, 1997, 6(4): 343-346
作者姓名:齐隽 闵志廉
作者单位:第二军医大学长征医院全军泌尿外科中心,长征医院协作病房
摘    要:目的:分析肾移植后免疫抑制剂对长期存活的影响,寻找移植后不同时间合适的免疫抑制用药方案及其用药剂量。 方法:对肾移植一年以上、肾功能正常的497例患者进行5年连续随访。根据移植后2、3、5年的不同免疫抑制用药将患者分为三联、二联、传统二联治疗三组。统计各组的排异发生率,排异和无排异患者免疫抑制用药的种类、剂量及CsA浓度,对排异患者追踪排异发生前12个月内的药物更动情况。 结果:肾移植后2、3、5

关 键 词:肾移植 免疫抑制剂 治疗方案

A RETROSPECTIVE ANALYSIS OF DIFFERENT IMMUNOSUPPRESSIVE PROTOCOLS IN RENAL TRANSPLANTATION
Qi Jun,Min Zhilian,He Changming,Chang Jiwei,Liu Min. A RETROSPECTIVE ANALYSIS OF DIFFERENT IMMUNOSUPPRESSIVE PROTOCOLS IN RENAL TRANSPLANTATION[J]. Chinese Journal of Nephrology, Dialysis & Transplantation, 1997, 6(4): 343-346
Authors:Qi Jun  Min Zhilian  He Changming  Chang Jiwei  Liu Min
Affiliation:Qi Jun,Min Zhilian,He Changming,Chang Jiwei,Liu Min Department of Urology,Chang Zheng Hospital,Second Military Medical University
Abstract:OBJECTIVE Different protocols of immunosuppression have been used for renal transplantation with the combination of cyclosporine A(CsA) or Azothioprine(Aza) or prednison (P). To compare the long term effects of different protocols in renal transplantation patients, we retrospectively analyzed the data of our patients whose renal grafts maintained normal for at least one year. METHODOLOGY 497 renal graft recipients were included. All of them were followed up for more than five years and serum creatinine maintained normal for at least one year. The patients were divided into three groups, triple therapy(CsA Aza P), double therapy(CsA P) and traditional combined therapy (Aza P). The rates of allograft rejection for 2, 3 and 5 years were compared between the three groups, and comparison was made between patients with and without rejection in regarding to the immunosuppression protocol changes. RESULTS Allograft rejection rates of 2, 3 and 5 years post transplantation were respectively 4 95%( n =243), 4 93% ( n =223)and 5 65%( n =124) for triple therapy; 30%( n =10), 8%( n =25), 5 26%( n =38) for double therapy; and 7 69%( n =91), 12 35%( n =81), 5 10% ( n =98) for traditional combined therapy. In the analysis of the data from patients with rejection, we found most of them had a history of inadequate dosage tapering or withdrawal of CsA or Aza. CONCLUSION Triple therapy is the best immunosuppressive maintaining regimen. The most common cause of graft rejection was inadequate dosage tapering or withdrawal of CsA or Aza.
Keywords:transplantation kidney immunosuppression  
本文献已被 CNKI 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号